Bristol-Myers Squibb completed a €5 billion public offering of five series of notes through its subsidiary, BMS Ireland Capital Funding, with maturities ranging from 2030 to 2055. The company intends to use the proceeds, along with approximately $3.0 billion in cash on hand, to fund a tender offer for its outstanding notes and for general corporate purposes.
